Company logo

PYPD - PolyPid Ltd.

NASDAQ -> Healthcare -> Biotechnology
Petah Tikva, Israel
Type: Equity

PYPD price evolution
PYPD
(in millions $) 1 May 2024 31 Dec 2023 30 Sep 2023 30 Jul 2023
Current assets
Cash $3.84 $5.31 $1.35 $3.4
Short term investments $10.61 $8.8 $11.71
Net receivables $0.1
Inventory
Total current assets $15.09 $6.07 $11.12 $15.75
Long term investments
Property, plant & equipment $10.08 $9.22 $9.71 $10.42
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $25.4 $15.37 $20.93 $26.26
Current liabilities
Accounts payable $1.29 $0.77 $0.53 $0.9
Deferred revenue
Short long term debt $5.3 $4.54 $3.34 $2.71
Total current liabilities $9.2 $7.29 $5.9 $5.45
Long term debt $4.29 $6.38 $7.66 $8.54
Total noncurrent liabilities
Total debt
Total liabilities $18.25 $17.47 $17.39 $17.92
Shareholders' equity
Retained earnings -$244.76 -$238.31 -$231.95 -$226.35
Other shareholder equity
Total shareholder equity $7.14 -$2.1 $3.54 $8.35
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $5.31 $8.55 $9.82 $4.32
Short term investments $4.04 $22.38 $40.16
Net receivables $0.1 $0.24 $0.6
Inventory
Total current assets $6.07 $14.19 $34.81 $47.2
Long term investments
Property, plant & equipment $9.22 $11.68 $8.76 $5.89
Goodwill & intangible assets
Total noncurrent assets $28.65
Total investments
Total assets $15.37 $25.97 $44.23 $75.85
Current liabilities
Accounts payable $0.77 $1.14 $4.14 $0.97
Deferred revenue
Short long term debt $4.54 $4.98
Total current liabilities $7.29 $8.55 $7.81 $2.88
Long term debt $6.38 $7.57
Total noncurrent liabilities $0.19
Total debt
Total liabilities $17.47 $20.14 $8.01 $3.07
Shareholders' equity
Retained earnings -$238.31 -$214.44 -$174.62 -$132.29
Other shareholder equity
Total shareholder equity -$2.1 $5.83 $36.23 $72.78
(in millions $) 1 May 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $5.26
Operating income
Income from continuing operations
EBIT
Income tax expense $0.03
Interest expense -$0.32
Net income
Net income -$5.6
Income (for common shares)
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $22.87 $26.27
Operating income -$26.27
Income from continuing operations
EBIT
Income tax expense $0.07
Interest expense -$0.93
Net income
Net income -$23.86 -$36.87
Income (for common shares)
(in millions $) 31 Jan 2024 30 Jul 2023 29 Oct 2021 29 Jul 2021
Net income -$19.16
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$13.55
Investing activities
Capital expenditures
Investments
Total cash flows from investing $3.8 -$7.86 $15.64
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $9.98 $10.98 $1.03
Effect of exchange rate
Change in cash and equivalents -$3.46 -$5.16 $3.12
(in millions $) 31 Jan 2024 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$39.56 -$42.6 -$36.87
Operating activities
Depreciation $1.72 $1.12 $1.01
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$34.32 -$32.39 -$21.6
Investing activities
Capital expenditures -$1.77 -$2.65 -$0.78
Investments
Total cash flows from investing $3.8 $16.58 $36.9 -$40.77
Financing activities
Dividends paid
Sale and purchase of stock $4.75 $1.03 $62.77
Net borrowings $11.31
Total cash flows from financing $9.98 $16.43 $1.03 $62.77
Effect of exchange rate $0.53
Change in cash and equivalents -$3.46 -$1.31 $5.55 $0.41
Fundamentals
Market cap $19.52M
Enterprise value N/A
Shares outstanding 4.80M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share 0.80
EPS N/A
ROA N/A
ROE N/A
Debt/Equity -8.32
Net debt/EBITDA N/A
Current ratio 1.64
Quick ratio N/A